Association between epidermal growth factor receptor mutations and the expression of excision repair cross-complementing protein 1 and ribonucleotide reductase subunit M1 mRNA in patients with non-small cell lung cancer

Experimental and Therapeutic Medicine

Volumn 9, Issue 3, 2015, Pages 880-884

  Xu, Chun Wei ^a   Wang, Gang ^b   Wang, Wu Long ^b,c   Gao, Wen Bin ^b   Han, Chuan Jun ^b   Gao, Jing Shan ^d   Li, Yang ^a   Wang, Lin ^e   Zhang, Li Ying ^a   Zhang, Yu Ping ^f   Tian, Yu Wang ^a   Fang, Jin Nv ^g  

^a Beijing Military Hospital PLA   (China)

^b DALIAN UNIVERSITY   (China)

^c BAOTOU MEDICAL COLLEGE   (China)

^d DALIAN MEDICAL UNIVERSITY   (China)

^e Department of Pathology Shanxi Da Hospital Shanxi Academy of Medical Sciences   (China)

^f WEIFANG PEOPLE'S HOSPITAL   (China)

^g YANBIAN UNIVERSITY   (China)

Author keywords

Epidermal growth factor receptor; Excision repair cross complementing protein 1; Individualized treatment; Molecular detection; Non small cell lung cancer; Ribonucleotide reductase subunit M1

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; MESSENGER RNA; RIBONUCLEOTIDE REDUCTASE;

ADULT; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; POLYMERASE CHAIN REACTION; QUANTITATIVE ASSAY; RNA EXTRACTION;

EID: 84922012357     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2015.2196     Document Type: Article

References (26)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
2. Sher T, Dy GK and Adjei AA: Small cell lung cancer. Mayo Clin Proc 83: 355-367, 2008.
3. Cao C, Lu S, Sowa A, et al: Priming with EGFR tyrosine kinase inhibitor and EGF sensitizes ovarian cancer cells to respond to chemotherapeutical drugs. Cancer Lett 266: 249-262, 2008.
4. Herbst RS: Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59 (2 Suppl): 21-26, 2004.
5. Sharma SV, Bell DW, Settleman J and Haber DA: Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7: 169-181, 2007.
6. Chan SK, Gullick WJ and Hill ME: Mutations of the epidermal growth factor receptor in non-small cell lung cancer - search and destroy. Eur J Cancer 42: 17-23, 2006.
7. Simon GR, Ismail-Khan R and Bepler G: Nuclear excision repair-based personalized therapy for non-small cell lung cancer: from hypothesis to reality. Int J Biochem Cell Biol 39: 1318-1328, 2007.
8. Rosell R, Lord RV, Taron M and Reguart N: DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 38: 217-227, 2002.
9. Su C, Zhou S, Zhang L, et al: ERCC1, RRM1 and BRCA1 mRNA expression levels and clinical outcome of advanced non-small cell lung cancer. Med Oncol 28: 1411-1417, 2011.
10. Mok TS, Wu YL, Thongprasert S, et al: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 361: 947-957, 2009.
11. Olaussen KA, Dunant A, Fouret P, et al: DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 355: 983-991, 2006.
12. Bepler G, Kusmartseva I, Sharma S, et al: RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 24: 4731-4737, 2006.
13. Lynch TJ, Bell DW, Sordella R, et al: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139, 2004.
14. Paez JG, Jänne PA, Lee JC, et al: EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500, 2004.
15. Riely GJ, Pao W, Pham D, et al: Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib. Clin Cancer Res 12: 839-844, 2006.
16. Kobayashi S, Boggon TJ, Dayaram T, et al: EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792, 2005.
17. Ceppi P, Volante M, Novello S, et al: ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 17: 1818-1825, 2006.
18. Cobo M, Isla D, Massuti B, et al: Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 25: 2747-2754, 2007.
19. Pao W, Miller V, Zakowski M, et al: EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311, 2004.
20. Deng QH, Qiu Y, Mo MC, et al: EGFR gene copy number, ERCC1 and BRCA1 protein expression and their relationship in non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 33: 508-512, 2011 (In Chinese).
21. Lin XY, Chen Y and Chen ZZ: Expression of ERCC1 and RRM1 in non-small cell lung cancer (NSCLC) and clinical prognosis. Fujian Yike Daxue Xuebao 45: 10-14, 2011 (In Chinese).
22. Gandara DR, Grimminger P, Mack PC, et al: Association of epidermal growth factor receptor activating mutations with low ERCC1 gene expression in non-small cell lung cancer. J Thorac Oncol 5: 1933-1938, 2010.
23. Mitsudomi T, Morita S, Yatabe Y, et al; West Japan Oncology Group: Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11: 121-128, 2010.
24. Reynolds C, Obasaju C, Schell MJ, et al: Randomized phase III trial of gemcitabine-based chemotherapy with in situ RRM1 and ERCC1 protein levels for response prediction in non-small-cell lung cancer. J Clin Oncol 27: 5808-5815, 2009.
25. Simon GR, Schell MJ, Begum M, et al: Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis. Cancer 118: 2525-2531, 2012.
26. Hu YY, Zhang DB, Dong YG, et al: The protein expression and the significance of RRM1 and ERCC1 in non-small cell lung cancer. Shandong Yi Yao 52: 1-3, 2012 (In Chinese).